Pyrimidine compounds as kinase inhibitors

US9815847B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9815847-B2
Application numberUS-201414775917-A
CountryUS
Kind codeB2
Filing dateMar 13, 2014
Priority dateMar 14, 2013
Publication dateNov 14, 2017
Grant dateNov 14, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This disclosure relates to compounds, methods for their preparation, pharmaceutical compositions including these compounds and methods for the treatment of cellular proliferative disorders, including, but not limited to, cancer.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of formula (I): or a salt thereof, wherein: R 1 is CN, S(O) j Ar 1 , or S(O) k (C 1-6 alkylene)Ar 1 ; j is 0, 1 or 2; k is 0, 1 or 2; each Ar 1 is independently C 6-10 aryl or 5-10 membered heteroaryl, each of which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from Cy 1 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, C 1-6 haloalkyl, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , C(═NR e1 )NR c1 R d1 , NR c1 C(═NR e1 )NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , NR c1 C(O)NR c1 R d1 NR c1 S(O)R b1 , NR c1 S(O) 2 R b1 , NR c1 S(O) 2 NR c1 R d1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 and S(O) 2 NR c1 R d1 ; each Cy 1 is independently C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl, each of which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , C(═NR e1 )NR c1 R d1 , NR c1 C(═NR e1 )NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , NR c1 C(O)NR c1 R d1 , NR c1 S(O)R b1 , NR c1 S(O) 2 R b1 , NR c1 S(O) 2 NR c1 R d1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 , S(O) 2 NR c1 R d1 and oxo; A is NR 2B ; R 2A is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ar 2 or (C 1-6 alkylene)Ar 2 ; R 2B is H, C 1-6 alkyl, C(O)C 1-6 alkyl, Cy 2A , C(O)Cy 2A , (C 1-6 alkylene)Cy 2A and C(O)(C 1-6 alkylene)Cy 2A ; or R 2A and R 2B , together with the N atom to which they are attached, form a 5-, 6-, or 7-membered heterocycloalkyl group, which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , C(═NR e2 )NR c2 R d2 , NR c2 C(═NR e2 )NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , NR c2 C(O)NR c2 R d2 , NR c2 S(O)R b2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , S(O) 2 NR c2 R d2 and oxo; Ar 2 is C 6-10 aryl or 5-10 membered heteroaryl, each of which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from Cy 2B , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , C(═NR e2 )NR c2 R d2 , NR c2 C(═NR e2 )NR c2 R d2 NR c2 R d2 , NR c2 C(O)R b2 NR c2 C(O)OR a2 NR c2 C(O)NR c2 R d2 NR c2 S(O)R b2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 and S(O) 2 NR c2 R d2 ; Cy 2A is C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, or 5-10 heterocycloalkyl, each of which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from Cy 2B , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , C(═NR e2 )NR c2 R d2 , NR c2 C(═NR e2 )NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , NR c2 C(O)NR c2 R d2 , NR c2 S(O)R b2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , S(O) 2 NR c2 R d2 and oxo; each Cy 2B is independently C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, or 5-10 heterocycloalkyl, each of which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, NO 2 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , C(═NR e2 )NR c2 R d2 , NR c2 C(═NR e2 )NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , NR c2 C(O)NR c2 R d2 , NR c2 S(O)R b2 , NR c2 S(O) 2 R b2 , NR c2 S(O) 2 NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , S(O) 2 NR c2 R d2 and oxo; R 3A is H, Cy 3A1 or C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkynyl, wherein said C 1-6 alkyl forming R 3A is optionally substituted with 1, 2, or 3 substituents independently selected from Cy 3A2 , halo, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , C(═NR d3 )NR c3 R d3 , NR c3 C(═NR d3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , S(O) 2 NR c3 R d3 and oxo; R 3B is H, Cy 3B1 or C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkynyl, wherein said C 1-6 alkyl forming R 3B is optionally substituted with 1, 2, or 3 substituents independently selected from Cy 3B2 , halo, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , C(═NR d3 )NR c3 R d3 , NR c3 C(═NR d3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , S(O) 2 NR c3 R d3 and oxo; each Cy 3A1 , Cy 3A2 , Cy 3B1 and Cy 3B2 is, independently, C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, or 5-10 heterocycloalkyl, each of which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from R Cy3 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , S(O) 2 NR c3 R d3 and oxo; or R 3A and R 3B , together with the N atom to which they are attached, form a 5-, 6-, or 7-membered heterocycloalkyl group, which is unsubstituted or substituted by 3, 4 or 5 substituents independently selected from R Cy3 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , S(O) 2 NR c3 R d3 and oxo; each R Cy3 is independently selected from C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, 5-10 heterocycloalkyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, C 1-6 haloalkyl, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 NR c3 R d3 NR c3 C(O)R b3 NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , S(O) 2 NR c3 R d3 and oxo; wherein each of said C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl and 5-10 heterocycloalkyl forming R Cy3 is independently unsubstituted or substituted by 1, 2, or 3 substituents independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, C 1-6 haloalkyl, CN, NO 2 , OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , NR c3 R d3 NR c3 C(O)R b3 , NR c3 C(O)OR a3 , NR c3 C(O)NR c3 R d3 , NR c3 S(O)R b3 , NR c3 S(O) 2 R b3 , NR c3 S(O) 2 NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , S(O) 2 NR c3 R d3 and oxo; each R a1 , R b1 , R c1 , R d1 , R a2 , R b2

Assignees

Inventors

Classifications

  • containing three or more hetero rings · CPC title

  • One sulfur atom · CPC title

  • containing three or more hetero rings · CPC title

  • Two nitrogen atoms · CPC title

  • One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9815847B2 cover?
This disclosure relates to compounds, methods for their preparation, pharmaceutical compositions including these compounds and methods for the treatment of cellular proliferative disorders, including, but not limited to, cancer.
Who is the assignee on this patent?
Icahn School Med Mount Sinai
What technology area does this patent fall under?
Primary CPC classification C07D495/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).